Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
FDA expands label for Novartis and Roche’s blockbuster, converts EMD Serono’s NSCLC drug to full approval
The FDA on Friday signed off on an expanded label for Novartis and Roche’s blockbuster Xolair (omalizumab) and on Thursday converted the accelerated to full